

MINDCURE

A NOVEL SOLUTION TO THE
GLOBAL MENTAL HEALTH CRISIS

PAGES 4-6

GETTING A HEAD START
ON THE COMPETITION

PAGES 9-11

AT THE VANGUARD OF THE PSYCHEDELIC REVOLUTION

CSE: MCUR | O TC:MCURF



FUNDED FOR GROWTH WITH
REVENUES ON THE HORIZON

PAGE 17-18



A brand new avenue of treatment

As a co-founder of PayPal and the first outside investor in Facebook...

It's fair to say that the billionaire entrepreneur Peter Thiel knows how to spot an opportunity.

In fact, as well as being early to identify the need for online payment portals and the rise of social media, he also co-founded a company, Palantir Technologies, to claim a stake in the booming Big Data space too.

Bottom line is, when Thiel makes a move, smart investors should take note.


Question is: where is he going next?

The answer might surprise you.

Psychedelic medicine.

We're talking here about modern treatments derived from hallucinogen compounds like psilocybin, LSD, and MDMA.

This may sound unusual, especially given that many of the drugs themselves have long been banned.



But, as you'll see in this report, regulation is already beginning to ease due to new research showing just how effective psychedelics could be in helping to defeat today's global mental health crisis.

Even the US Food and Drug Administration (FDA) is lowering its guard where psychedelics are concerned.

Indeed, it's one of the many reasons Thiel has backed one particular psychedelics company with a \$12 million stake.

Over the coming months, this company is expected to list on the market with a valuation of between \$1 and \$2 billion.

And when it does, it is expected to spur a tidal wave of investment into the entire psychedelic sector – rapidly accelerating its move into the mainstream.

One under-the-radar company that could benefit the most as the wider market inevitably catches up with Thiel is MINDCURE ([CSE : MCUR](#) | [OTC:MCURE](#)).

Indeed, as you'll discover, this exciting Canadian firm has not just one, but two ground-breaking pieces

MIND

of proprietary Big Data technology that could put it in pole position to dominate the psychedelic space.

It has even assembled a team of influential scientific and regulatory experts and advisors to formulate and commercialize a range of patentable psychedelic treatment products and revolutionize the way therapists use psychedelics to treat patients.

When you see how undervalued this firm really is at the moment given its ambitious plans and its robust balance sheet...

You'll want to act quickly to claim your own stake before everyone else catches on.

CURE



A novel solution to the global mental health crisis

We are in the midst of a psychedelic revolution.

This may come as a surprise, but it's actually been about 50 years in the making.

Studies into the therapeutic qualities of psychedelic compounds date back as far as the 1950s, when trailblazing chemists like Albert Hoffman enjoyed great success.


Patients with mood disorders like depression, addiction, and OCD saw huge improvements after taking courses of hallucinogenic drugs.

But just as the door began to open, it was quickly slammed shut.

After becoming wrapped up in the counterculture movements of the sixties, psychedelics had been almost entirely outlawed worldwide by the early seventies.

For decades, scientific progress became almost impossible.

But today, the door has once again opened.



Leading universities like Johns Hopkins and Imperial College and institutions like MAPS have launched a new era of psychedelic research.

And they are delivering outstanding results.

Psychedelic compounds are proving to be extremely effective in addressing difficult-to-treat disorders like treatment-resistant depression and PTSD. They now look far superior to the antidepressants and SSRIs sufferers have been forced to use for decades.

In the face of a global mental health epidemic affecting around 13% of the world's population in one way or another, psychedelics have become impossible to ignore.

We're now seeing influential regulators like the FDA and Health Canada begin to cut away at the stringent red tape surrounding the sector.

In fact, the former has even given "breakthrough therapy" status to two research programmes, rapidly accelerating their investigations into psilocybin – the active ingredient in magic mushrooms.

With the future of psychedelic medicine looking so bright, the sector is attracting massive investor interest.

From the various universities opening dedicated, privately-funded psychedelic research arms...

To the growing group of listed psychedelic stocks that have now raised more than US\$500 million in financing...

More and more people are locking in ground floor exposure to this sector's huge commercial potential.

One under-the-radar stock positioned at the vanguard is MINDCURE.

It will only be a matter of time before the market clocks the gigantic profit potential of this recently listed firm's unique model and proprietary technology.

And when it does, early investors stand to make huge profits.

MINDCURE's Five Spheres

Product Discovery

Investigating Product Candidates and New Psychoactive Substances (NPS)

Investigating custom synthesis of product candidates and new psychoactive substances (NPS) or 'research chemicals'.

Nootropic Formulations

Manufacturing and Supply of Adaptogens

Identify, develop, and commercialize products that enhance mental health and wellness, ease suffering and increase productivity.

Clinical Research

Delivery of Psychoactive Therapy

Evaluating potential research programs, protocols, and supportive infrastructure to drive clinical research.

Seeking optimal outcomes and patient safety.

Digital Therapeutics Technology

Mental Health Platform

Digital Health integration to assess, coordinate, and monitor patient insights.

Formulation & Supply

cGMP and API Manufacturing and Supply

Investigating the manufacture, import and supply of traditional and novel psychoactive compounds:



Major returns from patented products

So, with psychedelic stocks flooding the market, what makes MINDCURE so unique?

Well, it all boils down to the organization's exciting commercial strategy.

You see, a lot of research in the emerging psychedelic medicine sector is focused on what the firm calls "classic compounds".

These are the chemicals we think of immediately when we hear the word "psychedelics" – LSD, MDMA, ketamine, psilocybin, etc.

The work is extremely valuable.

Any research breakthrough has a genuine shot at changing the lives


of millions – even billions – around the world for the better. That's why it is attracting large grants from the likes of the US military and the National Institute of Mental Health.

But the bottom line is, classic psychedelic compounds hold limited commercial potential from a drug development perspective.

How come?

Well, because these compounds have existed for decades, they cannot be patented.

The different types of mental health treatment medicines on the market



This means that even if a biotech firm were to prove that a classic compound offered unparalleled treatment to sufferers of a particular health issue...

It would not be able to use it in isolation to develop market-dominating products from which it can exclusively generate blockbuster profits.

This is why MINDCURE is taking a different approach.

Instead of using classic psychedelic compounds, it plans to develop its own products.

These could be combination therapies – classic psychedelic compounds used alongside one or more additional substances to achieve a desired effect.

Or they could be new molecular entities (“NMEs”) – unique derivatives of classic psychedelic substances altered in some way to change how they impact humans.

Either way, these products can be patented because they are MINDCURE’s intellectual property.

Imagine if even one were to pass through all the relevant clinical trials, receive regulatory approval, and become a colossal success.

MINDCURE would be the only firm who could profit before generic equivalents hit the market.

Given the psychedelic drugs market is set to be worth some US\$6.9 billion by 2027, **MINDCURE’s** patented products could hold the key to very significant revenues.



Getting a head start on the competition

MINDCURE knows it is unlikely to be the only first-mover to spot the immense commercial potential of developing patentable psychedelic products.

That's why it's given itself as big of a head-start as possible.

One of its major competitive edges is its patented bioinformatics platform PsyCollage, which has now passed through the beta testing phase.

It may sound complicated, but it's actually very simple.

PsyCollage – in layman's terms – brings the entire plethora of complex historical psychedelic drug research together within one central hub and breaks it down into key components. This can be anything from what receptors were targeted and what results were achieved to the methods used and the partners involved.

This information is then used to identify rapidly the illnesses (or "priority indications") where certain psychedelic compounds have demonstrated the most effectiveness.

So, why would a bioinformatics platform like PsyCollage be of use to MINDCURE?

Well, let's imagine that it didn't have the technology.

Identifying priority indications would involve pouring through thousands of research papers, painstakingly noting key takeaways and drawing conclusions manually.

This would cost a lot of money. But it would also take a lot of time.

It would be months – even years – before the firm would know where

to focus. Even longer still before it could enter the lab to begin product discovery.


PsyCollage accelerates the pre-clinical stage of the development cycle enormously.

MINDCURE has already used the platform to identify a range of priority indications for three psychedelic compounds – psilocybin, ketamine, and ibogaine.


This includes psychological disorders, but it also extends into the realms of physical pain as well as neuroregeneration and repair.

The logo for MINDCURE features the word "MINDCURE" in a bold, white, sans-serif font. A small teal circle is positioned above the letter "I". The background of the entire page is a dark red with a faint, light-colored geometric pattern of overlapping hexagons and lines.


The classic psychedelic compounds on which MINDCURE is currently focused



PSILOCYBIN, PSILOCIN, BAEOCYSTIN and NME analogues



KETAMINE, KETAMINE-ANALOGUES, targeting well established receptors and receptor motifs



IBOGAINE, Novel synthetics of natural IBOGA-derived compounds and precursors

Priority Areas of Drug Discovery and Lead Optimization of proprietary NME's:

- Head Trauma
- Spinal Cord Injury
- Neuroregeneration (remediation)
- Idiopathic pain
- Depression
- AD(H)D, Addiction

Priority Clinical Indications (combos of classic psychedelics):

- Traumatic Brain Injuries (rehabilitation & recovery)
- Migraines
- Cluster Headaches
- Neuropathic Pain
- Treatment resistant mood disorders

Specifically, MINDCURE is now working to use these three compounds as the basis for combination therapies and NMEs that address pain, migraines, cluster headaches, and traumatic brain injury.

Best of all, because MINDCURE has patented PsyCollage, no one else can use it.

This means it could be very valuable to a Big Pharma player willing to spend big bucks on speeding up drug development in the future....

For the time being, MINDCURE is using the platform solely to accelerate its own movement into the lab.

And this is where the company's second key competitive advantage comes into play...

Best-in-class team ready to lead the way

Kelsey Ramsden, president and CEO of MINDCURE, is a big deal in Canadian business.



Kelsey Ramsden
President and CEO

Twice-named the country's Top Female Entrepreneur, she has built multiple eight-figure companies from the ground up. Not only that, but she also serves on the Entrepreneurship Council for the University of Western Ontario.

Today, there is little to stop her replicating her success to date at MINDCURE.

She has assembled a team of renowned scientific leaders and regulation specialists at her firm.

These individuals not only give MINDCURE the very best chance possible of discovering and formulating new psychedelic products...

But they'll help move them down the tough clinical path to commercialization.

Take Dr. Ryan Hartwell, who heads up MINDCURE's scientific operations.



Dr. Ryan Hartwell, PhD
CSO

Dr. Hartwell was the co-founder of leading wound care player ATS Biotech. He also has first-hand experience in FDA, EU, HC, CFDA, and Japanese filings for drug products and medical devices. He brings a wealth of experience to the firm's regulatory affairs and product research capacities.

Then there's chief technology officer Geoff Belair.

Belair is a 30-year fintech veteran who most recently created the Integration Services Team at banking solutions company Fincentric.



Dr. Dan Engle, MD
Primary Investigator

Beyond the boardroom, MINDCURE also boasts some of the psychedelic sector's most influential figures as advisors.

Perhaps the best example is primary investigator Dr. Dan Engle.

Dr. Engle is renowned the world over for his specialization in psychedelic research, and is a regular guest on "The Joe Rogan Experience" and "The Tim Ferris Show".

In 2017, he authored "The Concussion Repair Manual", a guidebook for recovering from traumatic brain injuries ("TBIs"). With TBIs contributing to some

32,000 daily deaths in the US alone, the book quickly became a hit – celebrated by both physicians and professional athletes to this day.

Today, Dr. Engle is using his unparalleled expertise to advance MINDCURE's investigations into psychedelic compounds and TBIs.

There's also fellow advisor Hamilton Morris.

Known as the "Anthony Bourdain of psychedelics", Morris is a chemist, filmmaker, and journalist. He is renowned worldwide for his series "Hamilton's Pharmacopeia", which saw him explore the chemistry and traditions surrounding all manner of psychoactive drugs.

Today, Hamilton is bringing his insights to MINDCURE as it uses similar psychedelic products specifically to reduce pain and suffering in humans.

All told, MINDCURE's team and tech give it the biggest head start possible as it begins the journey into product discovery.



Hamilton Morris
Advisor

*iSTRYM*TM – A therapeutic tool like no other

The current model for psychedelic-assisted therapy is flawed.

A bold statement? Yes.

But let's look at how it works.

Patients suffering from a particular illness or disorder are enrolled into a psychedelic research programme and meet up with clinicians throughout.

Each time, their progress is evaluated for a couple of hours, tests are completed, and then they are left to their own devices.

This provides a good picture of how the patient is responding to treatment on the day of their session.

But what about all the time between sessions when they are not being monitored?

These periods make up the vast majority of a patient's life, and they could potentially provide therapists and researchers with ground-breaking insights into how they are responding on a day-to-day basis.

Another problem is the fact that psychedelic therapy research typically exists in cloistered scientific communities.

In short, the conclusions and data these researchers are producing could transform the way therapists treat their patients, they just aren't very accessible.

All told, these gaps create disparities in the collection of critical insights that arise outside of psychedelic-assisted therapy sessions and ultimately prevent new scientific breakthroughs.

To address this, MINDCURE has developed *iSTRYM*TM.

*iSTRYM*TM is a proprietary, centralized management system for therapeutic insights that can be used by therapists, patients, and researchers alike.

The platform has an app component, which allows patients to record real-time data like weather, their location, their mood, their heart rate and many other metrics that take place after therapy sessions and throughout therapeutic integration...

It also brings together the large database of protocols, data, and procedures gleaned from psychedelic research around the world to date.

Using AI and strategic data loops, it continually aggregates new – and potentially extremely useful – insights based on the largest collection of psychedelic research and ongoing mental optimization data in the world.

Everyone involved in the psychedelic-assisted therapy process benefit from iSTRYM™.

It arms therapists with the tools they need to provide personalized care with deeper insights and long-tail support, while increasing clinic revenue, reducing clinic hours, and increasing positive patient outcomes...

It gives patients the power to be informed and autonomous participants in their mental wellness journey, with AI that consistently works to understand them and provide supportive content...

And it enables psychedelic researchers to deliver results faster with cleaner data and deeper, richer insights.

iSTRYM™ is a Big Data play that could help millions around the world on the road to recovery.

The platform is also the fastest route to revenue in a psychedelic sector where the widescale rollout of products is likely to be several years down the line.

Best of all, because it is proprietary, only MINDCURE can offer it.

Just think of the commercial value it could hold to researchers looking to advance their research as quickly and effectively as possible.

Critically, the platform also supports MINDCURE in the progression of its own research programmes.

The company has completed a strategic investment and commercial cooperation deal with ATMA Journey Centers.

Based in Calgary, ATMA was the first organization to provide psychedelic-assisted therapy to a patient in Canada.

And together, the pair plan to roll iSTRYM™ out across ATMA's network of clinics in Canada and around the world.

MINDCURE and ATMA's agreement will support ATMA's therapists and patients, granting them access to real-time patient data and the wider world of psychedelic research to improve treatments and outcomes.

MINDCURE


But it will also enable ATMA to participate in MINDCURE’s research programs focused on pain, neuroregeneration, migraines, and cluster headaches.

The patient data iSTRYM™ gathers and the subsequent insights it makes will be enormously useful to MINDCURE’s researchers in their work to develop products.

It’s another excellent way for the firm to push forward in the long-term race to create patentable psychedelic products that can generate sizeable revenues.

And it’s no coincidence that we are now seeing some of the biggest players in the psychedelic space develop their own digital therapeutics platforms.

Other psychedelic companies developing digital therapeutic platforms



MindMed

— MindMed to Launch’s Digital Medicine Div. “Albert”, for Psychedelic Medicines¹



ATAI
LIFE
SCIENCES


ATAI dives into digital therapeutics to boost mental health care.¹

—  IntroSpect

ATAI Life Sciences’ new digital therapeutics company, IntroSpect, will create digital tools to “magnify” the effects of ATAI’s portfolio of drugs.²



“In the future we plan to expand our research into additional digital technologies to complement and augment our therapies.”³



mindstrong

— “developing technology for remote patient monitoring and mental health symptom measurement.”⁴

Funded for growth with revenues on the horizon

As we have shown, MINDCURE clearly has a lot of irons in the fire.

These irons all have the chance to be extremely profitable. But their development also requires funding.

MINDCURE knows this, and that's why it has ensured it is as well capitalized as possible as it pushes forward.

There's its balance sheet...

Following a C\$3.6 million raise in November last year and a C\$23 million bought deal in February

2021, the firm has roughly C\$22 million of cash lining its coffers as at writing.

But there's also another trick up its sleeve...

The company has developed a range of "nootropic products" that help to improve mental performance.

These include three functional mushroom powders focused on energy, immunity, and focus, and an additional product focused exclusively on teenager wellness.

Some of MINDCURE's nootropic products



Because these nootropic products contain only legal substances like mushrooms and are sold as dietary supplements, the route to market is much quicker than for psychedelics.

In fact, MINDCURE's entire nootropic range is on track to hit online stores and select fitness clubs before end-Q1 2021.

Most importantly, they have the potential to be a real money spinner for the company.

The nootropic market is thriving, with more and more consumers shifting towards wellness products and companies injecting vast sums into product R&D.

Functional Mushrooms are a rich source of antioxidants and may offer cognitive, digestive and immunity benefits as well as aid in boosting energy levels.

As a result, the space is expected to be worth some US\$6 billion by 2027 – that's up from US\$2.2 billion in 2019.

Even a small market share would provide MINDCURE with strong internal funding, reducing shareholder dilution as it pursues its psychedelic opportunities.



The time to get in is now

Given the massive commercial potential of its patentable psychedelic medicines...

Its revolutionary proprietary technology, that could change the face of psychedelic-assisted therapy and research...

And the strength of its balance sheet with the potential for near-term revenues...

MINDCURE looks like an absolute bargain right now.

The stock's current market cap only just covers its current cash balance. It attributes hardly any value at all to its long-term upside.

You only have to look at the valuations of some of the company's peers to see how valuable a strong position in this sector can become. Today, the likes of MindMed and Compass Pathways are worth more than US\$1 billion.

Good news is, there are plenty of catalysts on the horizon that could see MINDCURE re-rate more in line with these leading players.

On a micro level, the firm will begin to make nootropic revenues and will deploy cash into psychedelic product and technology development. The potential for market-grabbing breakthroughs here is huge.

Meanwhile, on a macro level, the psychedelic sector is poised to enjoy a new tidal wave of interest.

It stems from a global biotech company operating in the realm of psychedelic mental illness solutions called ATAI Life Sciences.

ATAI is slated to go public in late Q1 or early Q2 2021 with an IPO valuation of between US\$1 billion and US\$2 billion.

The last psychedelic player to list at anywhere close to this sum was Compass Pathways back in September 2020. And when it did, it attracted immense new interest in the psychedelic sector that led the value of almost every associated stock to sharply increase in a matter of days.

The key difference is, Compass listed with a valuation of US\$544 million...

If ATAI can hit the market with a valuation in the forecast range, one can only imagine the inflows it will bring to the wider psychedelic sector.





Given how undervalued it is already, and given the commercial potential of its model, MINDCURE could be positioned to soar the most.

Particularly with the company recently being included in the first-ever psychedelics ETF, marking it out definitively as a quality stock.

Bottom line is, MINDCURE is unlikely to stay this cheap for long.

The time to invest is now.

**MINDCURE
vs
Industry Peers**

	Integrated Therapy	New Psychedelic Substances	Protocol Distribution Strategy	Technology	AI Protocol Enhancement & Integration Optimization	Protocol Partnership Model
MINDCURE	●	●	●	●	●	●
 field trip	●	●		●		
 COMPASSION <small>Navigating Mental Health Pathways</small>	●	●	●			
 mindmed	●	●	●	●	●	
 mindstrong				●		

Ten reasons to add MINDCURE to your portfolio today

1

Exciting strategy to generate investor returns with patentable psychedelic medicine and Big Data tech

6

Strong cash balance recently re-capitalized through C\$23 million fund raise

2

Best-in-class management team and advisory board driving products forward

7

Near-term revenues from roll out of nootropic product range

3

Highly under-valued, with current market cap barely outstripping cash

8

Wider psychedelic sector opening up and attracting massive funding

4

PsyCollage rapidly accelerates product development pathway for a head start on peers

9

Recent inclusion on the first psychedelics ETF solidifies increases exposure

5

iSTRYM™ brings together patient and global psychedelic research data to improve outcomes for patients and therapists

10

Re-rate on the cards as ATAI Life Sciences listing attracts immense sector interest.

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the "Publisher") is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by MINDCURE's agency of record, SandStone Media to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher's ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company's CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual's financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company's actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company's operations; the size and growth of the market for the company's products and services; the company's ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company's business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here <https://www.valuethemarkets.com/terms-conditions/> and acknowledge that you have reviewed the Disclaimer found here <https://www.valuethemarkets.com/disclaimer/>. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

AUTHOR: VALUETHEMARKETS

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.